-
Je něco špatně v tomto záznamu ?
Drug-induced sprue-like intestinal disease
Hugh James Freeman
Jazyk angličtina Země Spojené státy americké
- Klíčová slova
- sprue-like střevní onemocnění, sprue podobné enteropatie, nezařazená sprue, malé střevní onemocnění vyvolané léky, post-colectomy enteritis, biologické léky, olmesartan,
- MeSH
- alkoholické nápoje MeSH
- antibakteriální látky MeSH
- antiflogistika nesteroidní MeSH
- bezlepková dieta MeSH
- celiakie * diagnóza etiologie chemicky indukované imunologie patofyziologie prevence a kontrola MeSH
- imunosupresiva MeSH
- ipilimumab MeSH
- kolchicin MeSH
- lidé MeSH
- methotrexát MeSH
- neomycin MeSH
- vinblastin MeSH
- vinkristin MeSH
- Check Tag
- lidé MeSH
Celiac disease is a gluten-dependent small intestinal disorder with characteristic, but non-specific histopathological features. A number of disorders may cause similar changes in small intestinal biopsies, but fail to respond to a gluten-free diet. Traditionally, infectious agents, such as giardiasis, were often believed to be responsible, but in many patients with a sprue-like intestinal disorder, other causes were detected. The list continues to expand with the emergence of “new” diseases, including transplant enteropathy, distinct immune deficiency syndromes and postcolectomy enteritis, as well as new treatments. Many medications may cause a sprue-like small intestinal mucosal inflammatory process. Alcohol, antibiotics (eg., neomycin), non-steroidal anti-inflammatory drugs (eg., sulindac), stathmokinetic and chemotherapeutic agents (eg., colchicine, vincristine, methotrexate) and immunosuppressive medications (eg., azathioprine, mycophenolate mofetil) may all cause sprue-like small intestinal mucosal changes. A number of “new” drugs have also been recently recognized to cause a sprue-like intestinal disease. These include pharmaceuticals, such as olmesartan, an angiotensin II receptor antagonist used in treatment of hypertension, and biologicals, specifically ipilimumab, a humanized monoclonal antibody designed to overcome cytotoxic T-lymphocyte antigen-4, used in treatment of some advanced malignancies, including malignant melanoma. Increased physician awareness for medication-related sprue-like intestinal disease is critical as the list of emerging and novel medications expands.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15025278
- 003
- CZ-PrNML
- 005
- 20151116095015.0
- 007
- ta
- 008
- 150723s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.12691/ijcd-2-2-5 $2 doi
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Freeman, Hugh James $u Department of Medicine (Gastroenterology), University of British Columbia, Vancouver, Canada
- 245 10
- $a Drug-induced sprue-like intestinal disease / $c Hugh James Freeman
- 504 __
- $a Literatura
- 520 9_
- $a Celiac disease is a gluten-dependent small intestinal disorder with characteristic, but non-specific histopathological features. A number of disorders may cause similar changes in small intestinal biopsies, but fail to respond to a gluten-free diet. Traditionally, infectious agents, such as giardiasis, were often believed to be responsible, but in many patients with a sprue-like intestinal disorder, other causes were detected. The list continues to expand with the emergence of “new” diseases, including transplant enteropathy, distinct immune deficiency syndromes and postcolectomy enteritis, as well as new treatments. Many medications may cause a sprue-like small intestinal mucosal inflammatory process. Alcohol, antibiotics (eg., neomycin), non-steroidal anti-inflammatory drugs (eg., sulindac), stathmokinetic and chemotherapeutic agents (eg., colchicine, vincristine, methotrexate) and immunosuppressive medications (eg., azathioprine, mycophenolate mofetil) may all cause sprue-like small intestinal mucosal changes. A number of “new” drugs have also been recently recognized to cause a sprue-like intestinal disease. These include pharmaceuticals, such as olmesartan, an angiotensin II receptor antagonist used in treatment of hypertension, and biologicals, specifically ipilimumab, a humanized monoclonal antibody designed to overcome cytotoxic T-lymphocyte antigen-4, used in treatment of some advanced malignancies, including malignant melanoma. Increased physician awareness for medication-related sprue-like intestinal disease is critical as the list of emerging and novel medications expands.
- 650 12
- $a celiakie $x diagnóza $x etiologie $x chemicky indukované $x imunologie $x patofyziologie $x prevence a kontrola $7 D002446
- 650 _2
- $a bezlepková dieta $7 D055050
- 650 _2
- $a alkoholické nápoje $7 D000434
- 650 _2
- $a antibakteriální látky $7 D000900
- 650 _2
- $a neomycin $7 D009355
- 650 _2
- $a kolchicin $7 D003078
- 650 _2
- $a vinkristin $7 D014750
- 650 _2
- $a vinblastin $7 D014747
- 650 _2
- $a methotrexát $7 D008727
- 650 _2
- $a antiflogistika nesteroidní $7 D000894
- 650 _2
- $a imunosupresiva $7 D007166
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ipilimumab $7 D000074324
- 653 00
- $a sprue-like střevní onemocnění
- 653 00
- $a sprue podobné enteropatie
- 653 00
- $a nezařazená sprue
- 653 00
- $a malé střevní onemocnění vyvolané léky
- 653 00
- $a post-colectomy enteritis
- 653 00
- $a biologické léky
- 653 00
- $a olmesartan
- 773 0_
- $t International journal of celiac disease $x 2334-3427 $g Roč. 2, č. 2 (2014), s. 49-53 $w MED00186448
- 856 41
- $u http://www.sciepub.com/journal/index.aspx?id=ijcd $y domovská stránka časopisu
- 910 __
- $a ABA008 $b B 2748 $c 280 $y 4 $z 0
- 990 __
- $a 20150723102837 $b ABA008
- 991 __
- $a 20151116095038 $b ABA008
- 999 __
- $a ok $b bmc $g 1085504 $s 908284
- BAS __
- $a 3
- BMC __
- $a 2014 $b 2 $c 2 $d 49-53 $i 2334-3427 $m International journal of celiac disease $x MED00186448
- LZP __
- $c NLK185 $d 20151116 $a NLK 2015-19/mk